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OBJECTIVES This study investigated whether apparently healthy relatives of patients with idiopathic
dilated cardiomyopathy (DCM) who have left ventricular enlargement (LVE) have biopsy
evidence of underlying myocardial disease.
BACKGROUND Left ventricular enlargement with normal systolic function is common among asymptomatic
relatives of patients with DCM. Although there is circumstantial evidence to suggest that
LVE may be a marker of early DCM, its pathophysiologic significance remains uncertain.
METHODS Over six years, 767 asymptomatic relatives of 183 consecutive patients with DCM were
evaluated: 37 (5%) had DCM and 104 (14%) had LVE (left ventricular end-diastolic
dimension 112% predicted) with normal systolic function. Right ventricular biopsy was
performed in 32 relatives with LVE, 14 patients with symptomatic DCM and 6 control
subjects with normal ventricular function undergoing elective coronary artery bypass graft
surgery. Histologic and immunohistochemical analyses, including quantitative double immu-
nofluorescence, were performed for leukocyte markers (CD3 and CD68), intercellular
adhesion molecule-1 (ICAM-1) and human leukocyte antigen class II antigens (DR and
DQ).
RESULTS Histologic findings consistent with DCM were present in 50% of the patients with DCM,
25% of the relatives with LVE and 0% of the control subjects. The median CD3 count was
2.4/mm2 in patients with DCM, 4/mm2 in relatives with LVE and 0 in control subjects (p
0.04). Using a threshold of 7 cells/mm2, 21% of patients with DCM and 25% of relatives
with LVE were CD3-positive (p  0.01). Quantitative analysis demonstrated DR expression
on 55.8 22.8%, 63.5 18.8% and 30.9 15.7% of the endothelial surface in patients with
DCM, relatives and control subjects, respectively (p  0.003). Corresponding values for
ICAM expression were 35.6  15.1%, 36.7  14.5% and 17.3  7.9% (p  0.013). When
combining inflammatory and histologic changes, 28 (86%) of LVE, 14 (100%) of DCM and
no control biopsies were abnormal (p  0.001).
CONCLUSIONS Most asymptomatic relatives of patients with DCM with LVE have histopathologic and
immunopathologic findings similar to those of patients with established disease. Clinical
identification and follow-up of such individuals are warranted to prevent presentation with
advanced DCM and to enable assessment of interventions aimed at attenuating disease
progression. (J Am Coll Cardiol 2002;39:455–62) © 2002 by the American College of
Cardiology
Idiopathic dilated cardiomyopathy (DCM) typically pre-
sents at an advanced stage of left ventricular dilation and
dysfunction and accounts for approximately one-third of all
new cases of symptomatic congestive cardiac failure and
50% of all patients undergoing heart transplantation (1).
The recognition, through recent prospective family evalua-
tion studies, that 25% of patients have familial disease (2–4)
raises the possibility that prognosis might be improved by
earlier diagnosis and treatment of relatives in a preclinical
phase of the disorder. Several mutations in genes encoding
for myocyte structural proteins have been shown to be
etiologic in individual DCM families (5–15), but the ability
to detect early disease by genetic screening is limited by the
fact that these mutations account for substantially 5% of
disease (16,17). We have previously reported that a propor-
tion of the apparently healthy relatives of patients with
DCM have isolated left ventricular enlargement (LVE), and
that this may be associated with serologic evidence of
immune activation, subtle physiologic abnormalities and
risk of progression to overt DCM (3,18,19). However, to
target potential therapies effectively and safely, a more
definitive demonstration of disease activity is required in
such individuals. Recent immunohistochemical studies have
shown that patients with DCM have increased expression of
human leukocyte antigens (HLAs) and cell adhesion mol-
ecules in the myocardial vasculature, as well as cellular
infiltration consistent with a chronic low-grade inflamma-
tion (20,21). The aim of this study was to determine
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whether similar histopathologic abnormalities are present in
apparently healthy relatives with LVE.
METHODS
Study group. Between January 1992 and December 1998,
prospective cardiovascular evaluation was offered to the
relatives of 370 consecutive patients with DCM attending
St. George’s Hospital in London. Evaluation of relatives
was offered to all patients with DCM, irrespective of the
presence or absence of a family history. A total of 198
patients consented to participate in the study. Evaluation of
asymptomatic relatives was approved by and performed in
accordance with the local ethics committee and has been
described in detail elsewhere (18). Evaluation included
clinical assessment, 12-lead electrocardiography and two-
dimensional echocardiography. Left ventricular cavity di-
mensions were corrected for age and body surface area
(BSA) according to the formula of Henry et al. (22):
percent predicted left ventricular end-diastolic dimension
(LVEDD)  measured LVEDD/predicted LVEDD 
100; predicted LVEDD (45.3 BSA0.3) (0.03 age)
 7.2. Relatives with known coronary disease, hypertension,
valvular disease or regular alcohol consumption of 21
U/week in men and 14 U/week in women were excluded
(1 U one-half ounce). In total, 767 relatives met inclusion
criteria. Of these, 552 (72%) were assessed as normal, 37
(5%) fulfilled World Health Organization criteria for DCM
(23), 25 (3%) had isolated, depressed fractional shortening
(25%) and 104 (14%) had LVE, defined as an unexplained
LVEDD 112% of predicted values in the presence of a
shortening fraction25% (18). A sample pedigree is shown
in Figure 1.
Thirty-two consecutive asymptomatic relatives from 25
families attending follow-up visits between January 1998
and June 1999 gave informed, written consent to undergo
right ventricular biopsy. The majority were first-degree
relatives, three were second-degree and one was a third-
degree relative. In addition, 14 consecutive patients with
confirmed symptomatic idiopathic DCM presenting during
the same period, who had not previously undergone myo-
cardial biopsy were studied. Control tissue was obtained,
following informed consent, from six patients undergoing
coronary artery bypass graft surgery for ischemic heart
disease without left ventricular dysfunction, with tissue
obtained at the time of operation from an area of the
ventricle not subtended by a diseased vessel. Specific ap-
proval for the biopsy protocol was obtained from the local
research ethics committee.
Myocardial biopsy. Patients and relatives underwent fluo-
roscopically guided right ventricular biopsy through the
right internal jugular vein. At least four samples were
processed for hematoxylin-eosin staining, and two speci-
mens were snap-frozen in Tissue-Tek (Sakura Finetek, Inc.,
Torrance, California) media in a cryo-mould and immedi-
ately transported on dry ice for storage at 80°C before
immunohistochemical analysis. In all cases, myocardial bi-
opsy was performed within three months of a diagnostic
echocardiogram.
Histology and immunohistochemistry. Specimens pro-
cessed for light microscopy were analyzed by an experienced
cardiac histopathologist (M. J. D.), who had no knowledge
of the identity and clinical details of the subjects. For
immunohistochemistry, serial 4-m frozen cryostat sections
were fixed in acetone for 3 min, incubated for 30 min with
mouse monoclonal antibodies to intercellular adhesion
molecule-1 (ICAM-1) (CD54, clone 6.5B5, Serotec, Ox-
ford, UK), HLA-DR (clone B.C10, Serotec), HLA-DQ
(clone SPV-L3, Serotec), CD3 (clone UCHT1, Serotec)
and CD68 (clone EBM11, Dakopatts, Glostrup, Den-
mark), washed for 15 min in phosphate-buffered saline and
incubated for 25 min with affinity-purified biotinylated goat
antibodies to mouse immunoglobulin G (IgG) (Dakopatts)
(gamma-chain specific). After further washing, the sections
were incubated with fluorescein isothiocyanate-conjugated
Abbreviations and Acronyms
BSA  body surface area
DCM  dilated cardiomyopathy
HLA  human leukocyte antigen
ICAM  intercellular adhesion molecule
IgG  immunoglobulin
LVE  left ventricular enlargement
LVEDD  left ventricular end-diastolic dimension
Figure 1. Pedigree of a dilated cardiomyopathy family. Solid symbols  affected individuals; half-solid symbols  asymptomatic relatives with left
ventricular enlargement.
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streptavidin (Dakopatts), which labels biotin at a ratio of 3
molecules of streptavidin to 1 molecule of biotin. On
sections stained for adhesion molecules and HLA markers,
rabbit IgG to factor VIII (Dakopatts) (endothelial cell
marker) was applied for 25 min and, after repeat washing,
the sections were incubated with tetraethylrhodamine
isothiocyanate-conjugated goat anti-rabbit IgG (Sigma,
Cambridge, UK). On sections stained for CD3 and CD68,
a propidium iodide nuclear stain was applied to facilitate cell
counting.
A Zeiss Axioplan (Herts, UK) photomicroscope with
ultraviolet epi-illumination equipped with filters for two-
color immunofluorescence was used. Cell counts were per-
formed using a grid system. The count for the entire section
was obtained, and the area of the specimen was measured
using an Optimax (Cambridge, UK) digitizing system to
determine cell counts per unit area. In accordance with
published data, an inflammatory cell count 7/mm2 was
considered elevated (24).
Image analysis was employed to quantify adhesion mol-
ecule and class II antigen expression. Double-exposure
images obtained from a Photonic-Sciences 3 chip (Millham,
UK) color-cooled camera were linked to a Kontron (Mu-
nich, Germany) 400 system for computer-assisted analysis.
The following measurements were obtained: 1) total area
expressing factor VIII (endothelium) as a percentage of the
area of the section; and 2) total area expressing both factor
VIII and HLA/adhesion molecule (i.e., endothelial-
expressed antigen) from double-exposed images. From
these measurements, the proportion of endothelial-
expressed antigen was calculated (thus controlling for po-
tential discrepancies in the amount of endothelium present
in each section). In addition, semiquantitative assessment of
staining intensity was performed in a standard fashion with
visual grading: negative (N); weak (1); moderate (2);
and high (3) (21). All analyses were performed by an
investigator blinded to the identity of the coded sections.
Figure 2 demonstrates double-staining for ICAM-1 and
endothelial markers in a biopsy specimen from a relative
with LVE.
Statistical analysis. All statistical analyses were performed
using SPSS for Windows (SPSS Inc., Chicago, Illinois). All
variables were tested for normality of distribution using the
one-sample Kolmogorov-Smirnov test. Comparisons be-
tween normally distributed continuous variables were per-
formed by means of the Student t test or by analysis of
variance for more than two groups. Comparisons between
continuous variables not normally distributed (CD3, CD68)
were performed using the Mann-Whitney U test or the
Kruskall-Wallis test for more than two groups. Correlations
between normally distributed continuous variables were
assessed using Pearson’s correlation coefficient. Correlations
between non-normally distributed continuous variables
(CD3, CD68) were assessed using Spearman’s rho. Com-
parisons between dichotomous variables were performed
using the chi-square test. A p value 0.05 was considered
significant. Results of normally distributed variables are
expressed in the text as the mean value  SD and those of
skewed variables are expressed as the median value (inter-
quartile range). Where graphically represented, normally
distributed continuous variables are expressed as the mean
value, with error bars indicating 1 SEM, and non-normally
distributed variables are expressed as the median value.
RESULTS
Patient characteristics. Myocardial biopsies were obtained
from all 32 relatives and 14 patients and, except for one case
of transient atrial fibrillation requiring cardioversion, all
procedures were uncomplicated. The mean age of patients
with DCM and relatives with LVE was 43.3  12.9 years
and 33.2  12.8 years, respectively (p  0.05). Seventy
percent of patients with DCM and 58% of relatives with
LVE were male. Echocardiographic variables are shown in
Table 1.
Histologic findings. Myocyte pleomorphism and intersti-
tial fibrosis consistent with DCM were observed in 50% of
the patients with DCM, 25% of relatives with LVE and 0%
of the control subjects (Table 1). No sample fulfilled the
Dallas criteria for myocarditis. There were few clinical
distinctions between individuals with and those without
abnormal histology. There were nonsignificant trends to-
ward older age (39.5 14.2 years vs. 34.6 12.6 years) and
longer follow-up before biopsy (22.7  26.5 months vs.
17.9  17.6 months) in individuals with abnormal histol-
ogy. A greater degree of ventricular enlargement and lower
systolic function in individuals with abnormal histology was
accounted for by the greater proportion of these individuals
in the DCM group and was not observed when the LVE
and DCM groups were analyzed separately.
Immunohistochemistry. There was a significant increase
in inflammatory cells (CD3, CD68) in both patients with
DCM and relatives with LVE, as compared with control
subjects (Table 1). Using the criterion of 7 cells/mm2,
21% of patients with DCM and 25% of relatives with LVE,
but no control subjects, were CD3-positive (p  0.01).
Visual assessment of adhesion molecules and class II anti-
gens using double immunofluorescence demonstrated pre-
dominantly endothelial expression of ICAM-1 and HLA-
DR. Expression of HLA-DQ was less prominent and was
predominantly interstitial. Quantitative assessment demon-
strated significantly higher expression of both HLA-DR
and ICAM-1 in patients with DCM and relatives with
LVE, as compared with control subjects. Quantitative
HLA-DR expression correlated significantly with quantita-
tive ICAM-1 expression (r  0.47, p  0.001), and
quantitative assessment correlated well with semiquantita-
tive measures for both markers (Fig. 3).
There were modest correlations between CD3 infiltra-
tion and quantitative assessment. Correlation coefficients
(Spearman’s rho) for CD3 counts with HLA-DR and
ICAM-1 expression were 0.451 (p 0.001) and 0.279 (p
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0.047), respectively. Percent HLA-DR expression in indi-
viduals positive for CD3 infiltration was 70.5  16.3%
versus 53.5 21.1% in individuals with7 cells/mm2 (p
0.02). Corresponding values for ICAM-1 were 38.9  16.2
and 33.4  15.1 (p  0.29).
Inflammation and histologic changes. Endothelial ex-
pression of antigen was nonsignificantly higher in individ-
uals without fibrosis than in those with fibrosis (HLA-DR:
62.7  21.6% vs. 58.2  18.5%; ICAM-1: 38.9  15.1%
vs. 31.2  12.8%). Similarly, counts of both macrophages
and CD3 cells were higher in individuals without fibrosis
than in those with fibrosis (66.8  35.2 vs. 51.4  42.8 and
4.4 vs. 2.1 [median values], respectively; p  0.05). Al-
though these values did not reach statistical significance,
trends for each marker of inflammation measured followed
the same direction (Fig. 4). In contrast with the findings in
Figure 2. Photomicrographs demonstrating expression of intercellular adhesion molecule-1 (A), endothelial staining (B) and double exposure (C) (40
magnification) in a biopsy from a relative with left ventricular enlargement.
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relatives with fibrosis, individuals with inflammation were
younger (29.6  12.4 years vs. 41.6  7.3 years, p  0.03)
than patients without inflammation and had been followed
for a shorter period before biopsy (17.4  20.6 months vs.
31.6  5.3 months, p  0.03).
DISCUSSION
Until now, evidence that LVE is a marker of early disease in
the relatives of patients with DCM has been indirect and
has included the demonstration of increased frequency of
circulating organ-specific antibodies (25) and abnormal
cytokine profiles, as well as abnormally low peak oxygen
consumption in these asymptomatic individuals (19). Pre-
liminary follow-up data also suggest that some relatives with
LVE progress to overt DCM (26). This study provides, for
the first time, to the best of our knowledge, direct patho-
logic confirmation that relatives with LVE have myocardial
disease, with inflammatory and/or chronic histopathologic
abnormalities present in the majority (86%) of these sub-
jects. This finding may have significant clinical and scientific
implications, including the potential, through detection of
preclinical disease, to prevent presentation with advanced
heart failure or a catastrophic event such as stroke or sudden
cardiac death; the facilitation of accurate labeling of relatives
for the purposes of genetic studies; and the opportunity to
study early-stage rather than advanced-stage disease in
which pathologic findings may be nonspecific and uninfor-
mative.
Nature of inflammatory changes in LVE. The inflamma-
tory changes identified in healthy relatives are not florid;
rather, they are indicative of a low-grade, indolent process
that resembles previously reported findings using sensitive
immunohistochemical methods in patients with established
cardiomyopathy (20,21,24,27). By incorporating quantita-
tive analysis and a control group to ensure specificity, we
have demonstrated significantly increased endothelial ex-
pression of adhesion molecules, class II antigens and in-
flammatory cell infiltration in relatives with LVE. Because
Table 1. Clinical, Histologic and Immunohistochemical Changes in Patients With DCM,












LVEDD (% predicted) 134  12.7 117  4.9 — 0.001
FS (%) 18.3  5.4 31.6  5.2 — 0.001
Holter 1,000 PVC/day 4 (28%) 8 (25%) — NS
Histologic changes 7 (50%) 8 (25%) 0 0.01
CD3 2.4 (0.6–5.4) 4 (1–7.5) 0 (0–2.6) 0.04†
CD68 53 (26–80) 58 (36–91) 40 (22–55) 0.2†
CD3-positive* 3 (21%) 8 (25%) 0 0.01
ICAM-1 35.6  15.1 36.7  14.5 17.3  7.9 0.013
HLA-DR 55.8  22.8 63.5  18.8 30.9  15.1 0.003
*7 cell/mm2; †Kruskall-Wallis test (nonparametric variable).
Data are presented as the mean value  SD, number (%) of patients or median value (interquartile range).
DCM  dilated cardiomyopathy; FS  fractional shortening; HLA  human leukocyte antigen; ICAM  intercellular
adhesion molecule; LVE left ventricular enlargement; LVEDD left ventricular end-diastolic dimension; PVC premature
ventricular contraction.
Figure 3. (A) Correlation between quantitative assessment of human leukocyte antigen (HLA)-DR and intercellular adhesion molecule (ICAM)-1 (r 
0.47, p  0.001). (B) Quantitative expression of HLA-DR in relation to visual assessment (error bars represent 1 SEM). The y axis represents the
percentage of endothelial expression. The x axis represents positive (Pos) grade 2 (moderate intensity) or grade 3 (high intensity) and negative (Neg)
grade 0 (negative) or grade 1 (weak intensity) by visual assessment. (C) Quantitative expression of ICAM-1 in relation to visual assessment.
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relatives with LVE are asymptomatic (i.e., normal systolic
function), the inflammatory process cannot be considered
secondary to LV dysfunction, such as has been observed in
individuals with clinical heart failure, irrespective of etiology
(28). Therefore, the results of this study suggest that
myocardial inflammation occurs early in the pathogenesis of
familial DCM.
Potential stimuli of inflammatory changes in LVE. The
primary stimulus or stimuli of this inflammatory process in
the relatives of patients with DCM remain to be elucidated,
but potential mechanisms include inherited myocyte struc-
tural protein defects (myocardial inflammation has been
demonstrated in individuals with DCM secondary to inher-
ited protein defects) (15), organ-specific autoimmunity
(25,29,30) and/or persistent viral infection (31). At this
time, we have not yet determined whether any of the
subjects in this study have an inherited cytoskeletal or other
myocyte protein defect. None of the families included had
prominent associated clinical features, which characterize
many of the genotyped families in the published data, such
as conduction system disease or skeletal myopathy (13,15).
Genetic evaluation of a number of families represented in
this study is in progress. A single gene defect has been
identified in only a minority of families with DCM.
Whether ongoing research will continue to uncover etio-
logic mutations accounting for the majority of cases, or
whether alternative processes account for different subsets of
familial cases, remains to be determined.
The finding of low-grade inflammation on biopsy is
consistent with other studies linking inflammatory processes
to the pathogenesis of familial DCM, ranging from HLA
associations (29) to circulating organ-specific antibodies
detectable in patients with DCM (25,30,32). In addition,
we have previously reported that circulating organ-specific
antibodies are present in asymptomatic relatives at a signif-
icantly higher frequency than in control subjects (25).
Whether these antibodies indicate a primary immunologic
etiology or a secondary process, and whether their presence
might prove a useful noninvasive marker of risk of progres-
sion remains the subject of ongoing investigation.
Viral infection is also a plausible candidate as a primary
inflammatory stimulus. Familial clustering of viral “myocar-
ditis” might be explained on the basis of inherited suscep-
tibility or common environmental factors, and asymptom-
atic relatives may be ideal individuals in whom to search for
viral persistence, because it has been demonstrated in an
animal model that the etiologic virus becomes undetectable
as the disease progresses to an advanced stage (31). How-
ever, nested polymerase chain reaction studies (with a
documented in-house lower limit of detection of one copy
unit) for the presence of enteroviral ribonucleic acid and
adenoviral deoxyribonucleic acid on endomyocardial biopsy
specimens from 19 of the relatives with LVE included in the
present study failed to show evidence of viral infection
among relatives (data not shown).
Relationship between inflammatory changes and fibrosis
in LVE and DCM. Analysis of the relationship between
fibrosis and inflammatory abnormalities and between these
and clinical variables prompts speculation on the time
course of events in the development of DCM. Fibrosis was
Figure 4. Relationship between markers of inflammation and the presence of chronic histologic changes of dilated cardiomyopathy. The y axis represents
the percentage of endothelial expression of antigen (intercellular adhesion molecule [ICAM] and human leukocyte antigen [HLA-DR]) or median cell
counts (CD68 and CD3). The error bars represent 1 SEM. The x axis represents the presence or absence of fibrosis and chronic myopathic changes.
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more commonly found in patients with established DCM
than in those with LVE, whereas inflammation tended to be
more marked among patients and relatives who did not have
fibrosis. These observations suggest that inflammatory pro-
cesses precede the development of typical histologic findings
in DCM, and that patients without these typical changes
may both be at greater risk of deterioration and have a
greater chance of full recovery, as compared with patients
with fibrosis who are at a more stable advanced stage of
disease.
The finding that 25% of relatives with LVE had histo-
logic findings similar to those of patients with DCM
suggests that some relatives with LVE may have, not early
disease as originally hypothesized, established disease. They
may represent genetically affected individuals with incom-
plete penetrance. They may also represent individuals who
have recovered from a phenotypically more obvious (albeit
unrecognized) disease state. This hypothesis is consistent
with recognized features of DCM, including a prolonged
asymptomatic prodrome and potential for partial or appar-
ently complete clinical resolution (33).
Study limitations. The prognostic significance of immu-
nohistochemical findings in relatives is not addressed in this
study. The absolute risk of progression in LVE remains to
be quantified. Preliminary data from an initial cohort have
demonstrated progression in 27% over a median of three
years, but longer term follow-up in a larger cohort is
required. Ultimately, the clinical challenge is to identify
more accurately, ideally using noninvasive markers, those
relatives who are at risk of disease progression or the
development of a serious complication. At this point, right
ventricular biopsy outside of the context of a research
protocol cannot be recommended for relatives with LVE.
A limited number of immunohistochemical markers were
assessed in this study, because it was not designed to
characterize the inflammatory process mechanistically, but
simply to determine whether immunohistochemical evi-
dence of myocardial inflammation was present in these
apparently healthy relatives. We can conclude that asymp-
tomatic relatives of patients with DCM with minor ven-
tricular abnormalities have myocardial disease. Whether
these low-grade inflammatory processes are central to the
pathogenesis of the DCM and determination of the primary
etiologic stimuli will require further study.
Individuals with isolated, depressed fractional shortening
were not studied, because this is less common than LVE in
relatives undergoing cardiovascular evaluation. However, it
is likely that this finding is also representative of underlying
disease and has also been incorporated as a minor criterion
into guidelines for family screening (26). By including
depressed fractional shortening, the proportion of asymp-
tomatic relatives with abnormalities potentially indicative of
underlying disease rises to 25%.
Conclusions. This study demonstrates that asymptomatic
relatives of patients with DCM with minor ventricular
abnormalities have histopathologic and immunopathologic
findings consistent with the presence of early or mild
myocardial disease. Because these ventricular abnormalities
are common among relatives, these findings have implica-
tions for the performance and interpretation of cardiovas-
cular evaluation in families of patients with DCM. The
ability to identify early disease will further our understand-
ing of the pathogenesis of DCM and provide a basis for the
evaluation of specific preventive therapy in relatives at risk.
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